Pharmaceutical Executive: What was Daiichi Sankyo's strategy for preparing for the JP Morgan Healthcare Conference? Ken ...

Hayley Burgess SVP, Inovalon, talks about how specialty pharmacists are evolving from dispensers into precision-care partners ...

Novartis has released an open letter addressed to the world’s governments, urging them to take action in addressing the ...

Regeneron's strategy focuses on a broad pipeline across six therapeutic areas, with significant near-term data readouts ...

On Thursday, January 15, 2026, President Trump announced The Great Healthcare Plan, his latest plan aimed at lowering ...

Graham Goodrich, CCO, Apnimed, points to 2026 as a pivotal year marked by Apnimed’s planned NDA filing for AD109, the ...

At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

Andy Timmerwilke is a Managing Director at Merrill (Bank of America) in Chicago advising high‑net‑worth families, executives, ...

Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...

A key number for Merck in the coming years is $70 billion. This is the mid-2030s revenue opportunity from potential new ...

Novavax entered the 2026 J.P. Morgan Healthcare Conference positioning itself as a partner-driven company focused on ...

AbbVie is focused on pipeline expansion and diversification to address the upcoming patent cliff, with significant financial ...